Stock News and Filings Feed
Mumbai: Carlyle Group, a global alternative asset manager with $170 billion of assets under management, is streamlining its operations in India by merging its growth and buyout investment departments as part of an effort to focus on more buyout transactions, according to two people aware of the development.
Here are a few top buzzing midcap stocks picked by CNBC-TV18's analysts in trade today -- Claris Lifesciences, SRF, Sun Pharmaceutical, JSPL, HDIL, Kaveri Seeds, Nalco, and NMDC.
Claris Lifesciences lost over 5 percent intraday on Wednesday as investors turned cautious regarding observations by US drug regulator.
Pharmaceutical company, Claris Lifesciences tumbled over 3% intraday on Wednesday based on media reports regarding the observations of US drug regulator.
City-based pharma player, Claris Lifesciences Ltd, said the company has completed the sale of its Global Generic Injectables Business to Baxter International Inc (USA) for an enterprise value of $625 million.
Claris Lifesciences on Thursday said it has completed sale of its global generic injectables business to Baxter International for an enterprise value of USD 625 million, or about Rs 4,200 crore.
Buying a house to just rent it out may not be a lucrative option in India, shows study of data provided by JLL India. Average rental yields were 3.1 per cent, as of May 2017, for top six cities in... »
WASHINGTON (Reuters) - Baxter International Inc (BAX.N) and Claris Lifesciences Ltd (CLAI.BO) have agreed to divest two types of pharmaceutical products to settle U.S. Federal Trade Commission charges that Baxter's proposed acquisition of Claris’ injectable drugs business is anticompetitive, the agency said on Thursday.
LONDON, July 12, 2017 /PRNewswire/ -- This report analyzes the worldwide markets for Clinical Nutrition Products in US$ Million. The Global market is analyzed by the following segments: Enteral Nutrition, Infant Nutrition, and Parenteral Nutrition.
Share price of Deerfield, IL-based Baxter International Inc. (BAX - Free Report) scaled a new 52-week high of $60.47 on Jun 21, closing a bit lower at $60.05. The company has gained around 3.68% over the past month, much better than the S&P 500’s addition of 1.98%.
Claris Lifesciences underwent an audit by the USFDA for pharmacovigilance in the last week of May and has not received any observation.
Claris Lifesciences gained 1.97% to Rs 333.50 at 11:15 IST on BSE after the company announced that it underwent a successful USFDA Pharmacovigilance audit.
11:50 am Escorts at record high: Escorts said its agri machinery segment in May sold 6,886 tractors, higher by 29 percent over 5,331 units sold in year-ago month. The growth on month-on-month basis was 41 percent, it added.
Claris Lifesciences zoomed nearly 12 percent intraday on Thursday after investors cheered the positive developments around US FDA inspection.
Share price of Deerfield, IL-based Baxter International Inc. (BAX - Free Report) scaled a new 52-week high of $59.49 on May 30, eventually closing a bit lower at $59.35. The company has gained around 17% over the past three months, much better than the S&P 500’s addition of 3%.
Baxter had sought FIPB approval to an equity investment of Rs4,020 crore in Claris Injectables through buying existing shares and subscription to fresh equity shares
The RBI on Wednesday said foreign buyers will not be able to buy any more shares in Fortis Healthcare and Claris Lifesciences as the prescribed limit has been reached.
Ahmedabad-headquartered pharma player Claris Lifesciences, which recently divested its stake in a joint venture, Otsuka Pharmaceutical India Pvt Ltd (OPIPL), might be looking at exiting the pharmaceutical business altogether.
The closure of the transaction is subject to regulatory approvals, including FIPB, after this CLL will not have any stake in Otsuka Pharmaceutical India.
The closure of deal between Claris Lifesciences and Otsuka is subject to certain regulatory approvals, including a nod from the Foreign Investment Promotion Board
Shares of Claris Lifesciences are surging over 3% in the early market hours of Tuesday’s trade on BSE.
Claris Lifesciences has a total of 40 abbreviated new drug applications filed with the US FDA, of which 16 have been approved
Listing and trading of the under mentioned security has been cancelled with effect from 30th March 2017.
After a long wait, the Republican proposal to repeal the Affordable Care Act (ACA, or Obamacare) with a replacement plan is on the table. While we are fast approaching the day when President Trump will finally replace the ACA and implement his "insurance for everybody" strategy, the nation is clearly divided into “we need” and “don’t need” camps.
Baxter International will partner with ScinoPharm Taiwan to develop, manufacture, and commercialize five injectable generic drugs for oncology and chemotherapy-related indications, the companies said today, through a collaboration whose value was not disclosed.